Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30660808 | 1.00 | MAPT (0.50) | MAPTMAPK1TDP1L3MBTL1MAOB | |
| SCHEMBL23355842 | 0.93 | MAOB (0.42) | MAPTMAPK1TDP1L3MBTL1MAOB | |
| SCHEMBL28398725 | 0.83 | TYMS (0.47) | MAPTMAPK1TDP1L3MBTL1MAOB | |
| SCHEMBL16072720 | 0.81 | KCNA3 (0.58) | MAPTMAPK1TDP1L3MBTL1MAOB | |
| SCHEMBL30930077 | 0.81 | ALOX15 (0.43) | MAPTTDP1 | |
| SCHEMBL9173435 | 0.80 | KCNA3 (0.56) | MAPTMAPK1TDP1L3MBTL1MAOB | |
| SCHEMBL9754264 | 0.79 | KCNA3 (0.63) | MAPTMAPK1TDP1L3MBTL1MAOB | |
| SCHEMBL8216313 | 0.78 | MAPT (0.69) | MAPTMAPK1TDP1L3MBTL1MAOB | |
| SCHEMBL21543800 | 0.78 | TTR (0.46) | MAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL25834309 | 0.77 | TOP1 (0.56) | MAPTMAPK1TDP1L3MBTL1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415345-B | Pyridazinone-based broad-spectrum anti-influenza inhibitors | 豪夫迈·罗氏有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3478671-B1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-05-13 | — | — | EP | disclosed |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-7115624-B1 | Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2006-10-03 | — | — | US | disclosed |
| EP-1214324-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2006-06-14 | — | — | EP | disclosed |
| US-6410556-B1 | ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2002-06-25 | — | — | US | disclosed |
| EP-1214324-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | disclosed |
| EP-1214060-A2 | METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001019830-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001017516-A2 | METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2001-03-15 | — | — | WO | disclosed |
| EP-0276436-B1 | PHOSPHINIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-06-16 | — | — | EP | disclosed |
| US-5006651-A | Rheumatic diseases, bone disorders | HOFFMAN-LA ROCHE INC. (US) | 1991-04-09 | — | — | US | disclosed |
| US-4885283-A | Phosphinic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0276436-A1 | Phosphinic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1988-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | ABCG2, PIR, PRNP | MAPT 1263/4885MAPK1 1411/4885TDP1 3657/4885 |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | ABCG2, PIR, PRNP | MAPT 1263/4885MAPK1 1411/4885TDP1 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.